Royalty Pharma PLC (RPRX)
| Market Cap | 32.48B |
| Revenue (ttm) | 2.01B |
| Net Income (ttm) | 2.22B |
| Shares Out | 370.00M |
| EPS (ttm) | 6.01 |
| PE Ratio | 8.64 |
| Forward PE | 18.94 |
| Dividend | $0.68 |
| Dividend Yield | 1.31% |
| Trading Day | January 15 |
| Last Price | $51.95 |
| Previous Close | $51.95 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 51.40 |
| Day's Range | 50.70 - 52.40 |
| Day's Volume | 4,324,219 |
| 52-Week Range | 35.99 - 52.40 |
Royalty Pharma plc said Friday its board has approved a 13% increase in its quarterly dividend to 17 cents a share. The dividend will be paid March 15 to shareholders of record as of Feb. 19.
NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2021 of $0.17 per cla...
NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that management will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, Janu...
NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced charitable contributions totaling $7,660,000 to support important COVID-19 research at The Rockefe...
NEW YORK, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an expansion of its leadership team:
NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma (Nasdaq: RPRX), BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Athyrium Capital Management, LP to...
Royalty Pharma invests in biopharmaceutical royalty streams and has deployed $18bn of capital into the space since 1996 - ~50% of all deployed capital. Its portfolio of assets includes royalti...
Royalty Pharma plc (RPRX) CEO Pablo Legorreta on Q3 2020 Results - Earnings Call Transcript
NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2020 and updated full-year 2020 guidance for Adjusted Ca...
Some of the drugs under Royalty Pharma's (RPRX) royalty acquisition agreements performed well during the third quarter while others declined or flatlined.
NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement to acquire the residual royalty interest in Vertex Pharmaceuticals, Inc.'s cystic fib...
Investing in biotech stocks may feel daunting to many investors, but these three stocks deserve to be on your watchlist. The post 3 Biotech Stocks With Eye-Catching Pipelines appeared first on...
NEW YORK, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today the closing of the secondary offering of 17,343,037 shares of its Class A ordinary...
NEW YORK, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma (Nasdaq: RPRX) today announced that it will report its third quarter 2020 financial results on Wednesday, November 11, 2020 before th...
NEW YORK, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today the pricing of the secondary offering of 17,343,037 shares of its Class A ordinary...
NEW YORK, Oct. 15, 2020 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2020 of $0.15 per class...
NEW YORK, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today that certain selling shareholders intend to offer an aggregate 17,343,037 of the C...
IPO stocks offer all sorts of risks and rewards. Here are seven new stocks to buy that represent the best of both worlds.
Although markets have pulled back so far in September, many are viewing this as a technical correction, as the markets ran very hot in a very strong August.
Royalty Pharma Discounted Despite High ROIC Business Model
NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has closed an offering of $6 billion senior unsecured notes, comprised of the following...
2020 is looking a whole lot like 1999, as technology initial public offerings that made little or no money came out and rocketed higher.
Royalty Pharma stock has faded after rallying immediately after its IPO. With valuation more reasonable, RPRX has a solid long-term case.
You'll have a rare chance to capitalize on two highly lucrative markets as Royalty Pharma stock profits from drugmakers in a different way. The post Royalty Pharma Is the Left-Field Investment...
Royalty Pharma PLC RPRX, +1.81% priced a $6 billion bond offering on Tuesday, joining the many companies issuing record levels of debt during the pandemic.
NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc announced today that it has priced an offering of $6 billion senior unsecured notes, comprised of the following tranches (colle...
Royalty Pharma's cash flow growth will power the stock higher. If cash flow continues at this pace, RPRX stock could rise by at least 88% over the next three years.
NEW YORK, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc announced today that it intends to offer, subject to market and other conditions, senior unsecured notes in multiple tranches (...
Royalty Pharma plc (RPRX) CEO Pablo Legorreta on Q2 2020 Results - Earnings Call Transcript
Royalty Pharma PLC (NASDAQ: RPRX) had a big initial public offering this summer, and it also reported earnings on Wednesday morning.
NEW YORK, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2020 and introduced full-year 2020 guidance for Adjus...
The second-quarter earnings reporting season may have peaked, but it is not over yet.
Biohaven will receive up to $250 million to fund zavegepant's development in migraine and non-migraine indications
The biopharmaceutical industry has been one of the most resilient in dealing with the coronavirus pandemic.
NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma (Nasdaq: RPRX) today announced the appointments of Henry A. Fernandez and Ted W. Love, M.D. to the company's Board of Directors, ef...
NEW YORK, July 20, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma (NASDAQ: RPRX) today announced that it will report its second quarter 2020 financial results on Wednesday, August 12, 2020, before ...
NEW YORK, July 20, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. (Nasdaq: PTCT) to acquire a portion of PTC’s royalty in...
The Renaissance IPO Index is up 37.7% year to date compared to -1.3% for the S&P 500. Here are seven new stocks to buy from this index.
Potential Royalty Pharma investors should wait until well after the lock-up period expires to buy RPRX stock.
Recent IPO by Royalty Pharma which acquires ownership interests in drug royalties is getting a lot of interest on Wall Street. Long-term investors may want to keep a close eye on RPRX stock Th...
An innovative model and a diversified base make Royalty Pharma stock interesting, particularly if a recent pullback continues The post Keep an Eye on Royalty Pharma Stock, 2020’s Biggest IPO a...
Spain's Pharma Mar is looking at listing on New York's Nasdaq market, joining a flurry of biotech companies aiming to tap investors' voracious appetite for the sector as it tests one of its th...
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit.
The market for initial public offerings has come roaring back, coinciding with the recovery of stock markets, hope for a V-shape economic recovery and a strong IPO market in June. The post IP...
VIRGINIA BEACH, Va., June 25, 2020 /PRNewswire/ -- New Ventures Funds, a venture fund targeting investments in companies across healthcare and life sciences, is pleased to announce the IPO of ...
Royalty Pharma is an interesting business and business model in the biopharmaceutical industry.
NEW YORK, June 18, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ: RPRX) today announced the closing of the initial public offering of 89,333,920 shares of its Class A ordinary shares p...
Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts be...
Jim Cramer: Newyly public Royalty Pharma is a great way to play biotech
"I think the story is so compelling that it's worth putting on a small position even up here," the "Mad Money" host said.
About RPRX
Royalty Pharma plc operates in the biopharmaceutical industry. The company operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry. It is involved in the identification, evaluation, and acquisition of royalties and royalty-related assets on various biopharmaceutical therapies. The company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio includes royalties o... [Read more...]
| Industry Biotechnology | IPO Date Jun 16, 2020 |
| CEO Pablo Gerardo Legorreta | Country United States |
| Stock Exchange NASDAQ | Ticker Symbol RPRX |
Financial Performance
In 2019, Royalty Pharma's revenue was $1.81 billion, an increase of 1.08% compared to the previous year's $1.79 billion. Earnings were $2.35 billion, an increase of 70.46%.
Analyst Forecasts
According to 8 analysts, the average rating for Royalty Pharma stock is "Buy." The 12-month stock price forecast is 52.14, which is an increase of 0.37% from the latest price.